Soluble Terminal Complement Complex (sC5b-9) Antikörper

Produktnummer ABIN181111

Dieser Maus Monoklonal Antikörper detektiert spezifisch Soluble Terminal Complement Complex in FACS, IHC (fro), WB und EIA. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Soluble Terminal Complement Complex (sC5b-9) Antikörper (ABIN181111)

Target: Soluble Terminal Complement Complex (sC5b-9)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Western Blotting (WB), Enzyme Immunoassay (EIA)

Klon: 3R2-0

Produktdetails

Produktmerkmale: Synonyms: Terminal complement complex, Membrane attack complex

Aufreinigung: Affinity Chromatography on Protein A

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise: ELISA. Western Blot. Flow Cytometry. Immunohistochemistry on frozen sections. Recommended Positive Control: Kidney from post streptoccal glomerulonephritis patients.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: Borate buffered saline, pH 8.4 containing 0.09 % Sodium Azide as preservative

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Haltbarkeit: 12 months

Antigendetails

Target: Soluble Terminal Complement Complex (sC5b-9)

Andere Bezeichnung: Complement SC5b-9 (TCC / MAC)

Hintergrund: Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190 kDa C5b which is bound to cells via 71 kDa C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75 kDa S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is therefore a reliable indicator of terminal complement pathway activation.Synonyms: Membrane attack complex, Terminal complement complex